News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Weather
E-Edition
Subscribe
Sign Up For Newsletters
News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Immunome, Inc.
< Previous
1
2
Next >
Immunome Appoints Phil Tsai as Chief Technical Officer
June 27, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Announces Completion of Purchase of Assets from Atreca
May 20, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Announces Promotion of Max Rosett to Chief Financial Officer
May 17, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Reports First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome to Present at 2024 Bank of America Healthcare Conference
May 08, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Appoints Kinney Horn as Chief Business Officer
May 02, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
April 05, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
March 28, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
March 26, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome to Participate in the Leerink Partners Global Biopharma Conference
March 07, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
March 01, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
February 20, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 16, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Announces Pricing of Public Offering of Common Stock
February 13, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Announces Proposed Public Offering of Common Stock
February 13, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
February 06, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
ADXS
IMNM
Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 05, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
January 08, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
ZNTL
Immunome Appoints Phil Roberts as Chief Technical Officer
January 04, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Appoints Carol A. Schafer to Board of Directors
January 02, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome to Acquire Antibody-Related Assets and Materials from Atreca
December 26, 2023
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome to Present at the Stifel 2023 Healthcare Conference
November 10, 2023
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Reports Third Quarter 2023 Financial Results
November 09, 2023
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Appoints Jean-Jacques Bienaimé to Board of Directors
November 08, 2023
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer
October 19, 2023
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies
October 03, 2023
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Reports Second Quarter 2023 Financial Results
August 09, 2023
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity
May 23, 2023
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Reports First Quarter 2023 Financial Results
May 05, 2023
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close